Zoster Vaccine Recombinant, Adjuvanted
Safety and Tolerability
National Heart, Lung, and Blood Institute (NHLBI)vaccinePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Safety and Tolerability cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Heplisav-B National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | B |
mkp10241 Mankind Pharma Limited | Phase 2 | CCC |
Capivasertib AstraZeneca | Phase 1 | CC |
Selvigaltin Galecto Biotech AB | Phase 1 | CC |
zp7570 Zealand Pharma | Phase 1 | CC |
Same molecule, other indications
Zoster Vaccine Recombinant, Adjuvanted is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →